Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Recommendation of “Buy” from Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has received a consensus recommendation of “Buy” from the eight ratings firms that are presently covering the stock, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $20.83.

ZVRA has been the topic of several analyst reports. Roth Mkm lifted their price target on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. JMP Securities initiated coverage on shares of Zevra Therapeutics in a research report on Tuesday, September 24th. They set an “outperform” rating and a $17.00 price target on the stock. William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Zevra Therapeutics in a research report on Monday, September 30th. Finally, Guggenheim began coverage on Zevra Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $20.00 target price on the stock.

Zevra Therapeutics Trading Up 2.3 %

ZVRA opened at $8.81 on Thursday. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00. The company’s 50 day simple moving average is $7.83 and its two-hundred day simple moving average is $6.29. Zevra Therapeutics has a 1-year low of $3.89 and a 1-year high of $8.95. The firm has a market capitalization of $463.58 million, a price-to-earnings ratio of -5.24 and a beta of 1.93.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. The business had revenue of $4.45 million during the quarter, compared to analysts’ expectations of $4.08 million. During the same period last year, the business earned ($0.15) earnings per share. Analysts expect that Zevra Therapeutics will post -1.63 EPS for the current fiscal year.

Institutional Investors Weigh In On Zevra Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. International Assets Investment Management LLC grew its position in Zevra Therapeutics by 594.0% in the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after purchasing an additional 5,940 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in shares of Zevra Therapeutics in the 1st quarter valued at approximately $64,000. Hunter Associates Investment Management LLC purchased a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at approximately $92,000. SG Americas Securities LLC purchased a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at approximately $105,000. Finally, City State Bank lifted its position in shares of Zevra Therapeutics by 14.1% in the 3rd quarter. City State Bank now owns 16,224 shares of the company’s stock valued at $113,000 after acquiring an additional 2,000 shares in the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.